High lipoprotein(a) raises your risk of cardiovascular disease and modestly raises your risk of dying earlier, but it does not prevent a long life. A landmark study of French centenarians found that people who lived past 100 actually had higher average Lp(a) levels than younger controls, and a greater share carried the small apolipoprotein(a) isoforms typically associated with elevated concentrations.1PubMed. Elevated lipoprotein(a) levels and small apo(a) isoforms are compatible with longevity: evidence from a large population of French centenarians That finding does not erase the risk, but it does reframe the question: the answer depends less on Lp(a) alone and more on the broader metabolic and inflammatory environment it operates in.
What the Mortality Data Actually Show
The Copenhagen General Population Study, which followed over 100,000 people, found that those with Lp(a) above roughly 93 mg/dL had about a 50% higher rate of cardiovascular death and a 20% higher rate of death from any cause compared to people with levels below 10 mg/dL.2PubMed. High lipoprotein(a) and high risk of mortality A 20% increase in all-cause mortality is real, but it is worth putting in perspective: it is far smaller than the risk from smoking, uncontrolled high blood pressure, or diabetes. It means that out of a large group of people with very high Lp(a), somewhat more will die during a given follow-up period than in a matched group with low Lp(a), but most will not.
A systematic review and meta-analysis pooling data from dozens of studies confirmed the connection, finding about a 33% higher rate of cardiovascular death in the general population for those with elevated Lp(a).3PubMed Central. Circulating lipoprotein (a) and all-cause and cause-specific mortality: a systematic review and dose-response meta-analysis The same meta-analysis found the risk was even steeper for people who already had diabetes, with roughly two and a half times the cardiovascular death rate. So while Lp(a) on its own is not a death sentence, it becomes considerably more dangerous when it layers on top of other metabolic problems.
The Centenarian Paradox
The French centenarian study deserves a closer look because it illustrates something important about how genetic risk factors work in practice. These individuals had significantly higher Lp(a) than a control group of younger, healthy adults, and more of them carried the small apo(a) isoforms that drive Lp(a) up.1PubMed. Elevated lipoprotein(a) levels and small apo(a) isoforms are compatible with longevity: evidence from a large population of French centenarians The researchers concluded plainly that high Lp(a) is “compatible with longevity.” How? Almost certainly because these centenarians had protective factors elsewhere: favorable genetics for inflammation, blood pressure, glucose metabolism, or some combination that offset the Lp(a)-driven risk. Longevity is the product of hundreds of genetic and environmental factors interacting simultaneously, and a single elevated biomarker rarely overrides all the rest.
How Lp(a) Causes Damage
Understanding the mechanism helps explain why high Lp(a) is harmful in some people and apparently tolerable in others. Lp(a) promotes atherosclerosis through several overlapping routes. It delivers cholesterol directly into artery walls, where it accumulates in the inner lining at concentrations that can exceed those of ordinary LDL cholesterol.4European Cardiology Review. Presumed Mechanisms Underlying Lipoprotein(a)-caused Atherosclerosis It carries oxidized phospholipids, which trigger inflammation and oxidative stress in blood vessel cells.5PubMed. The role of oxidized phospholipids in mediating lipoprotein(a) atherogenicity And it interferes with the body’s ability to dissolve blood clots: because of its structural resemblance to plasminogen, the protein that breaks down clots, Lp(a) competes with plasminogen for binding sites and slows fibrinolysis.6PubMed Central. Investigation of the Influence of Lipoprotein(a) and Oxidized Lipoprotein(a) on Plasminogen Activation and Fibrinolysis
Each of these pathways is influenced by the surrounding biochemical environment. If your arteries are already inflamed, Lp(a) has more opportunity to do damage. If your LDL cholesterol is very low, there is less total cholesterol being deposited in artery walls even if Lp(a) is high. This is why Lp(a) risk is not fixed: it depends heavily on what else is going on in your body.
The Factors That Amplify or Dampen Lp(a) Risk
Two modifiable factors have the strongest evidence for changing how dangerous elevated Lp(a) actually is: LDL cholesterol levels and systemic inflammation.
A large study from the Copenhagen population found that people with both high Lp(a) and high LDL cholesterol had roughly double the cardiovascular risk compared to those with low levels of both. But when LDL cholesterol was low, the excess risk from high Lp(a) essentially disappeared.7PubMed Central. Cardiovascular disease risk associated with elevated lipoprotein(a) attenuates at low LDL-C levels in a primary prevention setting A more recent participant-level meta-analysis, however, found that even among people on statin therapy who achieved low LDL cholesterol, Lp(a) above 50 mg/dL still carried about a 38% higher risk of atherosclerotic cardiovascular disease compared to those with lower Lp(a).8PubMed Central. Independence of Lipoprotein(a) and Low-Density Lipoprotein Cholesterol-Mediated Cardiovascular Risk: A Participant-Level Meta-Analysis The picture, then, is that lowering LDL helps a lot but may not fully neutralize Lp(a)-driven risk.
Inflammation may be the other key variable. The Multi-Ethnic Study of Atherosclerosis found a striking interaction: among people with low levels of high-sensitivity C-reactive protein (a blood marker of systemic inflammation), elevated Lp(a) was not associated with increased cardiovascular risk at any level. But when inflammation was elevated, Lp(a) above 100 mg/dL carried roughly double the cardiovascular risk. The combination of high Lp(a) and high inflammation was also independently tied to a 39% higher risk of dying from any cause.9PubMed Central. High-Sensitivity C-Reactive Protein Modifies the Cardiovascular Risk of Lipoprotein(a): Multi-Ethnic Study of Atherosclerosis This suggests that some of the centenarians with high Lp(a) may have survived precisely because they had low background inflammation.
Beyond Heart Attacks and Strokes
Lp(a) does not just affect the coronary arteries. One of the clearest secondary associations is with calcific aortic valve stenosis, a condition where calcium builds up on the heart’s aortic valve, gradually narrowing it and straining the heart. A meta-analysis of five studies found that people in the highest Lp(a) group experienced about 41% faster progression of aortic valve narrowing compared to those with the lowest levels.10JAMA Cardiology. Lipoprotein(a) and Calcific Aortic Valve Stenosis Progression: A Systematic Review and Meta-Analysis A separate study confirmed that levels above 100 mg/dL roughly doubled the risk of developing severe degenerative aortic stenosis requiring valve replacement, though this association did not hold for valve disease caused by bicuspid valves or rheumatic fever.11PubMed Central. Association of Lipoprotein(a) With Severe Degenerative Aortic Valve Stenosis
For people planning families, Lp(a) may also matter during pregnancy. A systematic review found that women with pre-eclampsia had Lp(a) levels about 12 mg/dL higher on average than women with normal pregnancies, and the association held for both early-onset and late-onset pre-eclampsia.12PubMed. Lipoprotein(a) in pregnancy: A systematic review and meta-analysis Whether lowering Lp(a) would prevent pre-eclampsia is unknown, but the connection is worth discussing with a doctor if you are pregnant and know your Lp(a) is high.
Why Your Ethnicity and Sex Matter
Lp(a) levels vary dramatically across populations, which complicates any single threshold for “high.” Black individuals tend to have the highest average Lp(a) concentrations of any ethnic group studied, followed by South Asians, then White, Hispanic, and East Asian populations.13PubMed. Lipoprotein(a) and ethnicities A U.S.-based study found that roughly 63% of non-Hispanic Black individuals tested had Lp(a) at or above 50 mg/dL, compared to about 31% of Mexican Americans.14PubMed Central. Lipoprotein(a) Levels in Disaggregated Racial and Ethnic Subgroups Across Atherosclerotic Cardiovascular Disease Risk Levels Despite these differences in distribution, the relationship between Lp(a) and cardiovascular risk appears to follow a similar gradient across groups, meaning higher is worse regardless of your starting point.15PubMed Central. The impact of Race and Ethnicity on Lipoprotein (a) Levels and Cardiovascular Risk
Sex matters too, particularly around menopause. The Copenhagen General Population Study found that women’s Lp(a) levels were about 27% higher after menopause compared to before, with a noticeable jump around age 50.16Atherosclerosis. Sex differences of lipoprotein(a) levels and associated risk of morbidity and mortality by age: The Copenhagen General Population Study A meta-analysis confirmed that postmenopausal women tend to have higher Lp(a) than premenopausal women, though it could not fully separate the effect of menopause itself from the effect of aging.17PubMed. The effect of menopause on lipoprotein (a) concentrations: A systematic review and meta-analysis For women with already-elevated Lp(a), the postmenopausal rise could push levels meaningfully higher and warrants monitoring.
What You Can and Cannot Do About Lp(a)
Lp(a) is overwhelmingly determined by genetics. The LPA gene single-handedly controls the vast majority of variation in Lp(a) levels, with carriers of small apo(a) isoforms producing concentrations up to five times higher than those with large isoforms.18PubMed Central. Lipoprotein(a) beyond the kringle IV repeat polymorphism: The complexity of genetic variation in the LPA gene Diet, exercise, and standard lipid-lowering drugs have little meaningful effect on Lp(a) itself. Statins, which are the cornerstone of LDL management, may actually raise Lp(a) in some people, particularly those who carry small apo(a) isoforms.19Atherosclerosis. Statin treatment increases lipoprotein(a) levels in subjects with low molecular weight apolipoprotein(a) phenotype One small study did report a significant Lp(a) reduction from a defined plant-based diet over four weeks, but this remains preliminary and has not been replicated at scale.20PubMed Central. Consumption of a defined, plant-based diet reduces lipoprotein(a), inflammation, and other atherogenic lipoproteins and particles within 4 weeks
The practical strategy for now centers on controlling everything around Lp(a) that you can control: keeping LDL cholesterol low, managing blood pressure, staying physically active, not smoking, and reducing systemic inflammation. These steps won’t change the number on your Lp(a) lab report, but they can meaningfully change what that number means for your actual risk.
For people with very high Lp(a) and progressive cardiovascular disease despite optimal management of other risk factors, lipoprotein apheresis is an option in some countries. This procedure physically filters Lp(a) out of the blood every one to two weeks. Studies of apheresis show a significant drop in cardiovascular events, with one long-term study reporting that the yearly major adverse cardiac event rate fell from 0.34 per patient to 0.006 per patient during treatment.21Journal of Clinical Lipidology. Long-term lipoprotein apheresis reduces cardiovascular events in high-risk patients with isolated lipoprotein(a) elevation Apheresis is burdensome and expensive, though, and is reserved for the highest-risk patients.
Drugs That May Change the Landscape
The most anticipated development is a class of RNA-based therapies designed to block production of apo(a), the protein unique to Lp(a), directly in the liver. Several drugs are in clinical trials, including pelacarsen, olpasiran, lepodisiran, and SLN360.22PubMed Central. Targeting Lipoprotein(a): Can RNA Therapeutics Provide the Next Step in the Prevention of Cardiovascular Disease? In a phase 2 trial, olpasiran reduced Lp(a) by over 95% at higher doses, with effects lasting months after a single injection.23PubMed. Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease Whether these dramatic reductions in Lp(a) actually translate into fewer heart attacks and longer lives is the central unanswered question. Phase 3 outcome trials are underway, and results are expected in the next few years. If these drugs prove effective and safe, they could fundamentally change the prognosis for people with genetically high Lp(a).
Should Everyone Get Tested?
Because Lp(a) is genetically fixed and does not fluctuate much over a lifetime (aside from the menopausal shift in women), a single measurement generally tells you everything you need to know. Expert consensus now favors measuring Lp(a) at least once in every adult, essentially treating it like a genetic risk factor that should be identified early and factored into long-term cardiovascular risk assessment.24PubMed Central. Consensus and guidelines on lipoprotein(a) – seeing the forest through the trees The relationship between Lp(a) and risk is linear and continuous, meaning there is no magic cutoff below which it is harmless and above which it is dangerous. Instead, risk calculators that integrate Lp(a) alongside traditional factors like age, blood pressure, and cholesterol give a more personalized picture.
Despite this, most people have never had their Lp(a) measured. Standard lipid panels do not include it, and many doctors still do not order it routinely. If you have a family history of early heart disease, aortic valve problems, or recurrent cardiovascular events despite well-managed risk factors, asking for an Lp(a) test is a reasonable step.
Living With the Knowledge
Finding out you have elevated Lp(a) can be unsettling, particularly because it is not something you caused and there are currently limited direct treatments. A survey of over 1,000 people with elevated Lp(a) found that about 71% reported minimal anxiety and about the same proportion had no regret about being tested.25PubMed. Experiences of people with elevated lipoprotein(a) and the impact on family and child screening But a separate large European study found that roughly 40% of participants who learned their Lp(a) was elevated reported significant concern or anxiety afterward.26PubMed Central. Cardiovascular endpoints and psychosocial challenges of lipoprotein(a) of 5726 participants in the ELITE-study over 5 years Part of the discrepancy may reflect how the information is communicated: patients who are told their risk can be modified by managing other factors may feel more empowered than those who leave the appointment with the impression that nothing can be done.
One piece of context that may help: Lp(a) may have originally evolved as a beneficial trait. It is found only in humans, Old World primates, and the European hedgehog, and one theory holds that it aided wound healing by binding to platelets and macrophages and promoting fibrin activation at injury sites.27PubMed. Lipoprotein (a) Evolution: Possible Benefits and Harm. Genetic and Non-Genetic Factors Influencing its Plasma Levels In a world where injuries and infections were the leading causes of death, faster clot formation and wound repair would have been advantageous. The cardiovascular harm it causes plays out over decades, well past the reproductive years when natural selection exerts its strongest pressure. This evolutionary mismatch helps explain why a risk factor this common persists in the human population: it was not always a liability.
What Matters Most for Your Lifespan
The honest answer to whether you can live a long life with high Lp(a) is that plenty of people do, but the odds improve substantially when Lp(a) is not stacking on top of other unmanaged risk factors. The combination of high Lp(a) with high LDL cholesterol and chronic inflammation is genuinely dangerous. High Lp(a) in someone with low LDL, low inflammation, good blood pressure, and no diabetes is a different situation entirely. The centenarian data make that case in the most dramatic way possible: these were people with Lp(a) levels that would alarm most cardiologists, and they outlived nearly everyone.
For now, knowing your Lp(a) gives you a reason to be more aggressive about the things you can change. Within a few years, drugs that directly lower Lp(a) by 90% or more may give people another tool. But even before those drugs arrive, the evidence strongly suggests that managing the metabolic environment around elevated Lp(a) matters more than the Lp(a) number itself.